News

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization ...
Investor's Business Daily on MSN51m

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

EU approves Gilead's new injection for preventing HIV

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...